General Medicine raises $120 million led by a16z, with Lilly and Mercy Health investing

General Medicine, a US healthcare store that lets customers search, compare and buy care, announced a $120 million Series B round on 6 October 2026, led by Andreessen Horowitz (a16z) ¹. Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup also took part, and Vineeta Agarwala, General Partner at a16z, led the investment ¹. The round takes the company's total funding to $152 million ¹.

What the company reports

General Medicine was founded in 2023 by Ashwin Muralidharan, Elliot Cohen and TJ Parker and launched nationwide in May 2025 ¹. Its catalogue now holds more than 2,900 products and services across medications, labs, telehealth, specialist e-consults and select in-person visits and procedures, with prices shown with and without insurance ¹.

The company says that since launch hundreds of thousands of customers have signed up, with an NPS average of 80 ¹. It reports that 83% of customers say it helped them address a health need they had been putting off, and that a third had delayed care for more than six months ¹. The average customer's health record spans 11 years and is presented to clinicians as a prioritised summary at the time of care ¹.

Customers can buy care directly, talk to a licensed clinician who is usually available the same day, or use the company's AI chat to explore symptoms or goals ¹. A licensed clinician decides what is clinically appropriate whenever clinical review is required ¹. The new money will be used to expand the store into more categories of care ¹.

TJ Parker joined full time as chief executive in October 2026, with Muralidharan, the founding chief executive, moving to chief product officer ¹. Parker was previously a General Partner at Matrix, where he led the company's early funding rounds ¹.

What it means for the market

The investor list puts a drugmaker and a health system on the cap table of a consumer care marketplace. General Medicine says investor and commercial relationships do not determine which products customers see or which treatments clinicians recommend ¹.

The company presents its catalogue as infrastructure for AI. It says the catalogue reconciles how customers, clinicians, insurers, laboratories and health systems each describe the same service, which makes pricing, comparison and clinical matching possible, and that the same infrastructure will allow an AI agent to shop on someone's behalf ¹. "Everyone's building a healthcare AI agent that can tell you what you might need. What's missing is the infrastructure that lets you actually get it," said Parker ¹.

Cohen, the company's president, framed price transparency as competitive pressure on incumbents. "When a customer can actually see their options and the price, the rest of the system has to compete," he said, adding: "That's true for a payer, a health system, or a drug manufacturer." ¹

Caveats

This piece rests on the company's own announcement. The customer numbers, the NPS score and the share of customers reporting delayed care are General Medicine's figures and have not been independently checked ¹. The release gives no revenue, valuation or detail of what Lilly or Mercy Health will do beyond investing ¹. The service operates in the United States only, and the release does not say when the new categories of care will be added ¹.